PHASE III TRIAL TO EVALUATE NEUROAID IN STROKE RECOVERY.(Clinical
report)
NeuroAid(TM) is the first natural compound to be studied in a large
clinical trial focused on stroke recovery starting in the acute stage.
The CHIMES study is a multi-center double-blind . . .
CHINESE SFDA GRANTS IMMTECH FAST TRACK STATUS.
Immtech Pharmaceuticals, Inc. (Amex: IMM) has announced that the
State Food and Drug Administration of the People's Republic of
China (SFDA) has granted Immtech's application Fast Track Status
for . . .
MEDICINOVA REPORTS POSITIVE RESULTS FOR PHASE I OF
MN-029.
MediciNova, Inc., San Diego, Calif., a biopharmaceutical company
that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and
the Hercules Market of the Osaka Securities Exchange (Code . . .
BIOLINERX IN-LICENSES NOVEL DRUG FOR ACUTE KIDNEY INJURY.
BioLineRx Ltd. (TASE:BLRX), Jerusalem, Israel's leading drug
development company, has signed a worldwide exclusive license agreement
with Gene Vector Technologies Ltd. for the development . . .
CLINICAL DATA ACQUIRES EPIDAUROS BIOTECHNOLOGIE AG.
Clinical Data, Inc. (NASDAQ:CLDA), Newton, Mass., has acquired
privately held Epidauros Biotechnologie AG of Bernried, Germany, in a
cash transaction valued at 8.75 million euros (or approximately . . .
INNEXUS UNVEILS DXL625 ANTI-CD20 MONOCLONAL ANTIBODY.
InNexus Biotechnology Inc., British Columbia, a drug development
company commercializing the next generation of monoclonal antibodies
based on its Dynamic Cross Linking (DXL(TM)) technology, has . . .
MED DISCOVERY/DRAXIMAGE SIGN COLLABORATION PACT.
Med Discovery and DRAXIMAGE, the radiopharmaceutical division of
DRAXIS Health Inc. (TSX: DAX) (NASDAQ: DRAX) have established a research
collaboration agreement to explore the combination of . . .
BIOLINERX STARTS PHASE II TRIAL OF BL-1020 FOR
SCHIZOPHRENIA.
BioLineRx Ltd. (TASE:BLRX), Israel's leading drug development
company, today announced the initiation of a Phase II clinical trial on
schizophrenic patients for the maximal tolerated dose . . .
TIKVAH LICENSES ACADEMIA SINICA NEURODEGENERATIVE
PATENTS.
Tikvah Therapeutics, Inc., Atlanta, and Academia Sinica of Taipei,
Taiwan announced today that Tikvah has entered into an exclusive
licensing agreement for a number of patent and patent . . .
STARPHARMA REPORTS POSITIVE RESULTS WITH VIVAGEL.(Financial
report)
Starpharma Holdings Limited, Melbourne, Australia, has presented
results of a clinical trial indicating that 3% SPL7013 Gel (VivaGel(TM))
was well-tolerated in men, and suitable for further . . .
BIOLINERX/UNIVERSITY OF ILLINOIS TO DEVELOP APOPTOSIS
AGENT.
BioLineRx Ltd. (TASE:BLRX), Israel's leading drug development
company, and the University of Illinois at Urbana-Champaign have
announced that they have entered into an exclusive worldwide . . .
ROSETTA/WEIZMAN INSTITUTE IDENTIFY ROLE OF MICRORNA.
Rosetta Genomics Ltd, (Nasdaq:ROSG), North Brunswick, N.J. a
leading microRNA company, announced today research published in the
journal Molecular Cell by scientists from the Weizmann Institute . . .
CHELSEA THERAPEUTICS INITIATES CH-150 BIOEQUIVALENCE
STUDY.
Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP), Charlotte,
N.C., has begun dosing volunteers in its bioequivalence study of
CH-1504, an orally available metabolically inert antifolate which . . .
HEMISPHERX INITIATES AMPLIGEN PHASE IIB FOR INFLUENZA.
Hemispherx Biopharma, Inc. (AMEX: HEB), has initiated a well-
controlled Phase IIb trial in Australia of Ampligen(r), an experimental
TLR3 ligand shown to function as an immune system activator , . . .
S*BIO INITIATES CLINICAL TRIAL OF NOVEL ANTI-CANCER DRUG.
S*BIO Pte Ltd has become Singapore's first biotechnology
company to initiate a Phase I clinical trial of a novel anti- cancer
compound. The compound, SB939, belongs to a new class of . . .
ONCOLYTICS BIOTECH GETS 21ST U.S. PATENT.
Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), Calgary has been
granted U.S. Patent 7,223,585 entitled "Viral Purification
Methods." The claims cover the production and purification of
viruses . . .
S*BIO/UNIVERSITY OF SINGAPORE PARTNER ON TUMOR
BIOAMARKER.
S*BIO Pte Ltd, a privately held biotech company focused on the
research and clinical development of novel targeted small molecule drugs
for the treatment of cancer, has entered into a two-year . . .
MIRCERA GETS POSITIVE OPINION IN EUROPE FOR ANAEMIA.
Roche, Basel, Switzerland, has received a positive opinion from the
European Committee for Medicinal Products for Human Use (CHMP)
recommending a marketing authorization be granted for MIRCERA for . . .
DRAXIS GETS ACCEPTABLITY AFTER INSPECTON OF
MANUFACTURING.
DRAXIS Health Inc. (TSX: DAX) (NASDAQ: DRAX), Mississauga, Ont.,
has received notification from the US Food and Drug Administration (FDA)
that the company's manufacturing operations in Montreal, . . .
SHIRE SIGNS DEAL WITH SAMARITAN TO LAUNCH REPAGAL FOR
FABRY.
Samaritan Pharmaceuticals Inc. (AMEX:LIV) a developer of innovative
drugs, has signed a second exclusive marketing and distribution
agreement, with Shire Human Genetic Therapies AB to launch and . . .
|
|